The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Key Points: SRC family kinases are activated in AML stem/progenitor cells and contribute to AML stem cell survival and proliferation. Combined inhibition of SFKs and c-KIT with dasatinib enhances p53-mediated elimination of AML stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951 · cited 1×
“Because HDM2 serine 166 phosphorylation is associated with enhanced p53 degradation, reduced phosphorylation could contribute to increased p53 in treated cells.(31) The combination of dasatinib and DNR also enhanced inhibition of SFK phosphorylation in AML CD34(1) CD38 and CD38(1) cells (supplemental Figure 7B) and re…”
BackgroundFusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732
Dumaz, N., & Meek, D. W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.24.7002 · Cited by 455
Montero, J. C., Seoane, S., Ocaña, A., & Pandiella, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2616 · Cited by 298
Cited by
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
“Among other compounds showing p53-mediated senescence is Dasatinib, a Src and c-Kit kinase inhibitor that is currently used in the clinic (103).”
BackgroundDasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice
Cavalcante, M. B., Saccon, T. D., Nunes, A. D. C., Kirkland, J. L., Tchkonia, T., Schneider, A., & Masternak, M. M. (2020) · Aging · doi:10.18632/aging.102772 · Cited by 80
“The use of dasatinib also increased p53 acute myeloid leukemia stem cell gene expression [54].”
BackgroundSeipel, K., Marques, M. A. T., Sidler, C., Mueller, B. U., & Pabst, T. (2018) · Haematologica · doi:10.3324/haematol.2018.191650 · Cited by 45
“PDGFR and VEGFR-2 are expressed in the bone marrow of AML patients(24,25) and, like FLT3, signal via PI3K/AKT and MDM2 to inhibit p53.(26,27) The stem cell growth factor receptor KIT is expressed in the bone marrow and, like FLT3-ITD, signals via PI3K/AKT and MDM2 to inhibit p53, and via JAK2 and STAT5.”
Background
Metadata
- Authors
- Dos Santos, C., McDonald, T., Ho, Y. W., Liu, H., Lin, A., Forman, S. J., Kuo, Y.-H., & Bhatia, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-09-12
- Volume
- 122
- Issue
- 11
- Pages
- 1900-1913
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2005400731
- Cited by
- 97
- References
- 4
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. https://app.cochat.ai/papers/10.1182/blood-2012-11-466425
- The paper
- Dos Santos, C., McDonald, T., Ho, Y. W., Liu, H., Lin, A., Forman, S. J., Kuo, Y.-H., & Bhatia, R. (2013). The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood. https://doi.org/10.1182/blood-2012-11-466425
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.